Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

What Is the Amylin Receptor? CTR and RAMP Proteins Explained

Conceptual illustration of three membrane receptor complexes, each pairing the same CTR core with a differently coloured RAMP partner.

The amylin receptor is a two-protein complex: a calcitonin receptor (CTR) paired with a receptor activity-modifying protein (RAMP). It functions as a heterodimer rather than as one standalone receptor protein.[1] Pairing CTR with RAMP1, RAMP2 or RAMP3 gives AMY1R, AMY2R or AMY3R, respectively.[2] These complexes belong to one receptor family, but their different partners produce distinct agonist selectivity and signalling profiles.[3]

Which proteins make up the amylin receptor

CTR is the receptor for the peptide hormone calcitonin and supplies an important peptide-binding surface within the amylin receptor complex. Experiments targeting its extracellular domain identify specific CTR residues involved in binding peptide fragments.[1] The RAMP is the accessory partner, but “accessory” does not mean pharmacologically unimportant: RAMP association changes the conformational behaviour of CTR and helps distinguish the resulting amylin receptors.[3]

The numbering follows the RAMP, not three separate amylin receptor core proteins:

  • AMY1R: CTR paired with RAMP1.
  • AMY2R: CTR paired with RAMP2.
  • AMY3R: CTR paired with RAMP3.

This architecture places the shared CTR component and the variable RAMP partner in the same functional unit.[2] A finding at AMY1R therefore does not automatically establish the same result at AMY2R or AMY3R. The shared core explains their relationship; the different partners explain why identifying the subtype matters.

What the RAMP subunit changes: trafficking and pharmacology

Conceptual comparison of CTR alone and three CTR–RAMP complexes, with translucent outlines suggesting different patterns of protein flexibility.

At the amylin receptor, the RAMP is a pharmacological determinant rather than merely a passive companion. CTR forms heterodimers with each of the three RAMPs to generate receptors with distinct agonist selectivity and signalling profiles.[3] Ligand preference concerns how a receptor responds to different agonists; signalling concerns the downstream response after engagement. These are related properties, but they are not interchangeable measurements.

A physical explanation comes from hydrogen–deuterium exchange mass spectrometry, or HDX-MS. In ligand-free receptor preparations, RAMP association differentially influenced the flexibility of CTR’s extracellular domain, transmembrane helices and intracellular regions involved in G protein engagement. The RAMPs also displayed subtype-specific dynamic signatures, particularly in their transmembrane and C-terminal regions.[3]

These results support an allosteric view: the partner changes the conformational landscape of the receptor, including regions beyond the extracellular peptide-binding surface. They connect receptor architecture with functional pharmacology without supplying a numerical affinity ranking for individual ligands. Because the measurements were made without a bound ligand, they describe differences already present in the unoccupied complexes, not a direct measurement of agonist-induced signalling.[3]

Trafficking concerns where a receptor is located and how it moves within a cell, rather than which peptide it prefers. RAMPs can regulate GPCR trafficking and pharmacology, and cell-line interaction mapping shows that their partnerships extend well beyond CTR.[4] That general finding does not specify a delivery route or the size of a trafficking effect for each amylin receptor subtype. Likewise, a conformational difference is not itself a measurement of receptor abundance at the cell surface.

CTR without a RAMP

Without a RAMP partner, the protein is CTR rather than one of the three CTR–RAMP amylin receptor complexes. CTR is itself the receptor for calcitonin.[1] RAMP association therefore changes the molecular entity being studied; it does not simply rename an unchanged receptor.

Receptor-level work shows that CTR alone and the CTR–RAMP complexes have different conformational behaviour. HDX-MS directly compared ligand-free CTR with complexes containing each RAMP, revealing partner-dependent changes in extracellular, transmembrane and intracellular flexibility. The same research describes distinct agonist selectivity and signalling profiles among amylin receptors.[3] A binding or signalling result obtained with CTR alone should consequently remain identified as a CTR result, not be relabelled as an AMY1R, AMY2R or AMY3R measurement.

The distinction becomes harder to isolate in an animal. Deleting RAMP1 and RAMP3 is not the same intervention as deleting CTR. In mice, that deletion weakened cagrilintide’s weight-lowering response but improved salmon calcitonin’s weight-loss efficacy.[2] The shifted response does not establish a specific in vivo function for unpaired CTR. It cannot by itself distinguish contributions from CTR alone, RAMP2-containing complexes or other consequences of removing the two RAMP proteins.

Ligands used to probe the amylin receptor

Amylin is a pancreatic beta-cell hormone. Its physiological actions include controlling satiation, slowing gastric emptying and limiting postprandial glucagon release. Its central actions also connect homeostatic eating controls with reward-driven behaviour.[5] These functions explain the interest in amylin-related pharmacology, but a physiological effect does not alone identify which receptor subtype carries it.

Salmon calcitonin is used in different experimental forms. A salmon calcitonin fragment served as a ligand in AMY1R extracellular-domain binding experiments, whereas the peptide was studied as a dual amylin–calcitonin receptor agonist in mice.[1][2] A fragment-binding result addresses a molecular interaction; a whole-animal response reflects more than that interaction alone.

Cagrilintide is also described as a dual amylin–calcitonin receptor agonist. In the mouse comparison, its body-weight effect was reduced by RAMP1/3 deletion, supporting a role for AMY1R and AMY3R in that response.[2] The joint deletion does not determine each subtype’s individual contribution or establish that AMY2R has no role.

An AC413 fragment carrying a Y25P substitution provided a contrasting antagonist-derived ligand in the AMY1R binding experiments. Its response to a receptor mutation differed from that of the salmon calcitonin fragment, illustrating that two peptides can depend differently on the same binding-pocket residue.[1]

What mutagenesis and knockout experiments can and cannot show

Two-panel conceptual illustration contrasting a receptor pocket with a highlighted residue and a laboratory mouse silhouette with a simplified neural network.

Mutagenesis tests how changing a receptor residue affects a measured property. In the AMY1R extracellular-domain study, D101A and N135A abolished peptide ligand binding, while N124A decreased affinity by more than eightfold. Replacing N124 with aspartate instead restored the salmon calcitonin fragment’s affinity but did not restore the AC413 fragment’s affinity.[1]

The contrasting N124 results are especially informative: changing one position can affect different ligands differently. They support a role for that position in ligand interaction, rather than a simple conclusion that every mutation weakens every peptide equally. However, the readout was binding affinity for peptide fragments, not downstream signalling. These measurements do not establish whole-animal potency or predict a human response.[1]

Knockout experiments instead ask whether an intact biological response depends on the deleted component. In wild-type mice, cagrilintide reduced body weight, whereas salmon calcitonin produced a small increase under the study conditions. Removing RAMP1 and RAMP3 weakened cagrilintide’s response and improved salmon calcitonin’s weight-loss efficacy.[2] Opposite changes after the same deletion show why the two ligands should not be treated as functionally interchangeable.

Neural measurements added another level of evidence. Both peptides activated cFos signals in the dorsal vagal complex and lateral parabrachial nucleus of wild-type mice. In cagrilintide-treated knockout mice, the area postrema cFos signal was 57% lower than in treated wild-type controls. Bulk mRNA sequencing also pointed to roles for RAMP1/3 in synaptic function and receptor trafficking.[2] These observations link the intervention to neural responses, but they do not isolate a particular receptor-binding event or prove a trafficking mechanism.

A joint RAMP1/3 knockout also cannot separate AMY1R from AMY3R contributions. Nor does the phenotype alone resolve direct receptor effects from developmental or circuit-level changes. The supported conclusion is dependence on those RAMP-containing receptor systems in this mouse setting, not a complete map of every receptor involved.

In vitro, animal and human evidence are not interchangeable

Each experimental level answers a different question. Receptor binding experiments identify molecular requirements for peptide interaction. HDX-MS characterises receptor conformational dynamics. Mouse knockouts test whether removing selected components changes an integrated biological response.[1][3][2] Agreement between these levels can strengthen an explanation, but one readout cannot substitute for another.

Human drug development is a further question. A review describes the translation of amylin biology into pharmacotherapy for obesity and diabetes, including long-acting analogues and combinations with other peptide hormones.[5] That clinical context does not turn mouse RAMP dependence into demonstrated human subtype dependence. Human efficacy, receptor selectivity and the contribution of a particular AMY subtype remain distinct claims requiring evidence appropriate to each question.

Related research: How Does Eloralintide Activate AMY1 Receptors?; What Is CagriSema? Cagrilintide + Semaglutide Combination — Research Overview.

Research Use Only Disclaimer: This article is for laboratory research and analytical education. It is not a validated experimental protocol or medical or veterinary advice. It provides no dosing, administration or personal preparation guidance; research materials are not for administration to humans or animals.

References

  1. Amylin Receptor 1 Mutagenesis Revealed a Potential Role of Calcitonin Serine 29 in Receptor Interaction — Song et al., Biomedicines, 2025
  2. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 — Carvas et al., EBioMedicine, 2025
  3. Conformational Dynamics of Amylin Receptors Revealed by Hydrogen-Deuterium Exchange Mass Spectrometry — Fairweather et al., Journal of the American Chemical Society, 2026
  4. Multiplexed mapping of the interactome of GPCRs with receptor activity-modifying proteins — Kotliar et al., Science Advances, 2024
  5. Amylin: A Multi-Functional Pancreatic Hormone — A Review — Le Foll and Lutz, Diabetes, Obesity and Metabolism, 2026